FAERS Noise Sparks LENZ Selloff – Citi Sees Buying Opportunity in VIZZ Stock

Citi calls the selloff in Lenz Therapeutics shares over a single FDA FAERS report "unwarranted," maintaining a Buy rating and $52 target on VIZZ eye drop concerns.